LON:DXRX Diaceutics (DXRX) Share Price, News & Analysis GBX 137.50 0.00 (0.00%) As of 12:30 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About Diaceutics Stock (LON:DXRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Diaceutics alerts:Sign Up Key Stats Today's Range 137.10▼ 137.7050-Day Range 112.50▼ 14052-Week Range 106▼ 151Volume334,198 shsAverage Volume146,093 shsMarket Capitalization£116.04 millionP/E RatioN/ADividend YieldN/APrice TargetGBX 175Consensus RatingBuy Company Overview At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®. Read More Receive DXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Diaceutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DXRX Stock News HeadlinesDiaceutics Appoints Lauren DeWitt as General CounselJuly 29, 2025 | tipranks.comDiaceutics Enhances Employee Incentives with Share PurchasesJune 6, 2025 | tipranks.comFOUR TRILLION DOLLARS!Nvidia just became the first company in history to hit a $4 trillion valuation—surpassing Apple and Microsoft. But one controversial analyst, known for predicting the collapses of Fannie Mae, GM, and others, is issuing a serious warning. He believes Nvidia’s rise has masked a dangerous flaw—and that the stock could fall 50% or more from current levels.August 8 at 2:00 AM | Porter & Company (Ad)Diaceutics PLC Announces AGM and Annual Report ReleaseMay 21, 2025 | tipranks.comDiaceutics PLC Expands Employee Share Incentive PlanApril 29, 2025 | tipranks.comDiaceutics PLC Enhances Employee Shareholding with New Share Incentive PlanApril 3, 2025 | tipranks.comDiaceutics PLC Aligns Employee Incentives with Share AwardsMarch 3, 2025 | tipranks.comDiaceutics Director Increases Stake Signaling Confidence in Company GrowthJanuary 31, 2025 | tipranks.comSee More Headlines DXRX Stock Analysis - Frequently Asked Questions How have DXRX shares performed this year? Diaceutics' stock was trading at GBX 123 on January 1st, 2025. Since then, DXRX shares have increased by 11.8% and is now trading at GBX 137.50. How were Diaceutics' earnings last quarter? Diaceutics PLC (LON:DXRX) released its quarterly earnings results on Tuesday, May, 13th. The company reported ($2.02) earnings per share (EPS) for the quarter. Diaceutics had a negative net margin of 10.90% and a negative trailing twelve-month return on equity of 7.15%. How do I buy shares of Diaceutics? Shares of DXRX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Diaceutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Diaceutics investors own include 4D pharma (DDDD), Rolls-Royce Holdings plc (RR.L), Abcam (ABC), B&M European Value Retail (BME), BP (BP), Coats Group (COA) and genedrive (GDR). Company Calendar Last Earnings5/13/2025Today8/08/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Diagnostics & Research Sub-IndustryN/A Current SymbolLON:DXRX CIKN/A Webwww.diaceutics.com PhoneN/AFaxN/AEmployees151Year FoundedN/APrice Target and Rating Average Price Target for DiaceuticsGBX 175 High Price TargetGBX 185 Low Price TargetGBX 160 Potential Upside/Downside+27.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)GBX (3.37) Trailing P/E RatioN/A Forward P/E Ratio136.03 P/E GrowthN/ANet Income-£2.84 million Net Margins-10.90% Pretax MarginN/A Return on Equity-7.15% Return on Assets-6.06% Debt Debt-to-Equity Ratio0.39 Current Ratio4.85 Quick Ratio9.92 Sales & Book Value Annual Sales£26.08 million Price / Sales4.45 Cash FlowGBX 44.07 per share Price / Cash Flow3.12 Book ValueGBX 45.87 per share Price / Book3.00Miscellaneous Outstanding Shares84,393,829Free FloatN/AMarket Cap£116.04 million OptionableNot Optionable Beta0.58 The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (LON:DXRX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | Sponsored#1 Pre-IPO Opportunity For 2025 [Take Action Now!]James Altucher has scored 37X and even 60X returns on past pre-IPO deals. But now he says a much bigger opport...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Diaceutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Diaceutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.